Effects of solriamfetol in a long-term trial of participants with obstructive sleep apnea who are adherent or nonadherent to airway therapy

STUDY OBJECTIVES: Solriamfetol, a dopamine/norepinephrine reuptake inhibitor, is approved in the United States and European Union to treat excessive daytime sleepiness in patients with obstructive sleep apnea (OSA) (37.5–150 mg/day) and narcolepsy (75–150 mg/day). This analysis evaluated solriamfeto...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Sleep Med
Main Authors: Schweitzer, Paula K., Strohl, Kingman P., Mayer, Geert, Rosenberg, Russell, Chandler, Patricia, Baladi, Michelle, Lee, Lawrence, Malhotra, Atul
Formato: Artigo
Idioma:Inglês
Publicado em: American Academy of Sleep Medicine 2021
Assuntos:
Scientific Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8020710/
https://ncbi.nlm.nih.gov/pubmed/33179591
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5664/jcsm.8992
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados